Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Phenobarbital
Drug ID BADD_D01752
Description A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Indications and Usage For the treatment of all types of seizures except absence seizures.
Marketing Status approved; investigational
ATC Code N03AA02
DrugBank ID DB01174
KEGG ID D00506
MeSH ID D010634
PubChem ID 4763
TTD Drug ID D0Y7RW
NDC Product Code 75826-142; 13517-626; 13517-628; 13517-758; 0121-0531; 51293-692; 54932-501; 63629-2399; 69367-214; 70752-163; 71205-892; 16571-673; 0143-1455; 0143-1458; 54932-207; 58118-0626; 60687-448; 62135-406; 62135-412; 63629-1033; 63629-2043; 63629-2045; 63629-2400; 70752-157; 70752-165; 70752-168; 71205-848; 72162-1584; 76003-0894; 13517-691; 16571-671; 0143-1500; 43063-953; 51293-693; 60687-671; 62135-405; 62135-410; 63629-1037; 63629-2402; 69367-172; 70518-2405; 70518-2418; 70518-3469; 70518-3470; 70752-164; 71205-851; 71205-891; 0603-1508; 0603-5165; 58118-1110; 64380-166; 70518-0911; 71205-890; 16571-669; 51293-691; 63629-1034; 63629-1038; 71205-845; 71205-846; 0603-5166; 75826-139; 75826-140; 50095-001; 66064-2001; 13517-625; 13517-627; 13517-693; 13517-757; 16571-672; 51293-627; 63629-2047; 63629-2291; 63629-2403; 70518-3471; 70752-167; 0603-5167; 72162-1583; 75826-143; 0904-6575; 13517-107; 13517-111; 13517-692; 13517-694; 17856-0174; 51293-625; 58118-1626; 62135-409; 63629-1035; 63629-1036; 63629-1039; 63629-2046; 63629-2049; 69367-211; 70518-2407; 70752-162; 13517-110; 13517-756; 16571-667; 16571-668; 16571-670; 0143-1495; 51293-694; 63187-895; 63629-2044; 63629-2289; 63629-2401; 63739-192; 63739-294; 69367-213; 71205-847; 71205-850; 0603-5168; 72162-1581; 75826-136; 75826-137; 51927-1015; 16571-675; 51293-628; 62135-407; 62135-411; 63629-1032; 63629-2041; 63629-2042; 63629-2048; 63629-2290; 69367-212; 70752-166; 71205-849; 71205-889; 71205-893; 72162-1582; 38779-0852; 51552-0745; 58624-0520; 59348-0011; 65319-1450; 62135-408; 63629-2404; 70166-536; 70166-537; 70518-2612; 70752-161; 75826-138; 75826-141; 13517-112; 13517-113; 13517-755; 16571-674; 17856-0678; 51293-626
UNII YQE403BP4D
Synonyms Phenobarbital | Phenylbarbital | Phenylethylbarbituric Acid | Acid, Phenylethylbarbituric | Phenemal | Phenobarbitone | Hysteps | Phenobarbital Sodium | Sodium, Phenobarbital | Phenobarbital, Monosodium Salt | Monosodium Salt Phenobarbital | Luminal | Gardenal
Chemical Information
Molecular Formula C12H12N2O3
CAS Registry Number 50-06-6
SMILES CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatitis09.01.07.0040.000325%Not Available
Hepatocellular injury09.01.07.008--Not Available
Hepatomegaly09.01.05.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hyperthermia12.05.01.002; 08.05.01.0010.000325%Not Available
Hypocalcaemia14.04.01.004--
Hypohidrosis23.02.03.005; 08.01.03.029--
Hypotension24.06.03.0020.000650%
Hypothermia12.05.03.001; 08.05.01.0030.000488%
Hypoventilation22.02.01.007--Not Available
Hypoxia22.02.02.003--
Injection site reaction12.07.03.015; 08.02.03.0140.000325%
Insomnia19.02.01.002; 17.15.03.002--
Intraocular pressure increased13.07.04.002--Not Available
Irritability08.01.03.011; 19.04.02.013--
Jaundice09.01.01.004; 23.03.03.030; 01.06.04.0040.000488%Not Available
Lactic acidosis14.01.01.0020.000325%Not Available
Laryngospasm22.04.02.002--
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.0030.001040%
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
Loss of consciousness17.02.04.0040.000325%Not Available
Mental disability26.01.01.001--Not Available
Metabolic acidosis14.01.01.0030.000325%Not Available
Mood swings19.04.03.001--Not Available
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Myocarditis02.04.03.0010.000325%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene